Does radiation therapy impair the immune system?

radiotherapy tolerance tests

The immune defenses can be impaired by dysfunction or a reduction in the number of white blood cells. Unlike chemotherapy that has a systemic action (i.e. in the whole body), radiotherapy has a localized action.. Therefore, it does not strongly decrease the number of circulating blood cells (cytopenia), unlike some chemotherapy drugs that have a direct toxic effect on blood cells (red blood cells, white blood cells, platelets). Nevertheless, in specific situations, a decrease in blood cells can be observed, particularly in patients who are undergoing or had previously received chemotherapy. Moreover, in pelvic or spinal irradiation, radiotherapy can decrease the number of cells at sites of blood cell production, located in the bone marrow of vertebrae and pelvis (iliac crests). However, only in exceptional cases this depletion has a clinical impact.

Radiotherapy hair loss

Notez cet post

FIRST TESTS TO PREDICT A PATIENT’S RADIOSENSITIVITY

NovaGray develops and commercializes the first radiotherapy tolerance tests for patients treated for breast or prostate cancer.

Performed before the start of radiotherapy with a simple blood draw, the tests assess the patients’ individual radiosensitivity and determine their risk of developing late complications after radiotherapy.

WHY DO A RADIOSENSITIVITY TEST?

Knowing a patient’s individual radiosensitivity is important information that can help:

  • Reassure the patient in preparation for radiotherapy
  • Guide physicians in choosing the most appropriate treatment plan
  • Adapt patient follow-up after radiotherapy

Team NovaGray

NovaGray develops radiotherapy tolerance tests for breast and prostate cancer patients. NovaGray's mission is to help personalize cancer treatment by assessing each patient's individual sensitivity before starting radiotherapy. NovaGray technology has been validated by multi-center prospective clinical trials. NovaGray tests are recommended by the French Society of Radiation Oncology (SFRO).